<VariationArchive VariationID="1073240" VariationName="NM_000137.4(FAH):c.96dup (p.Gly33fs)" VariationType="Duplication" Accession="VCV001073240" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-04-20" DateCreated="2021-05-10" MostRecentSubmission="2024-04-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1063426" VariationID="1073240">
      <GeneList>
        <Gene Symbol="FAH" FullName="fumarylacetoacetate hydrolase" GeneID="2184" HGNC_ID="HGNC:3579" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q25.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="80152789" stop="80186949" display_start="80152789" display_stop="80186949" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="80445232" stop="80478923" display_start="80445232" display_stop="80478923" Strand="+" />
          </Location>
          <OMIM>613871</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000137.4(FAH):c.96dup (p.Gly33fs)</Name>
      <CanonicalSPDI>NC_000015.10:80158073:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="80158073" stop="80158074" display_start="80158073" display_stop="80158074" variantLength="1" positionVCF="80158073" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="80450415" stop="80450416" display_start="80450415" display_stop="80450416" variantLength="1" positionVCF="80450415" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
      </Location>
      <ProteinChange>G33fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.80158074dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.80158074dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.80450416dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.80450416dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012833.1" sequenceAccession="NG_012833" sequenceVersion="1" change="g.10076dup">
            <Expression>NG_012833.1:g.10076dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000137.4" sequenceAccession="NM_000137" sequenceVersion="4" change="c.96dup" MANESelect="true">
            <Expression>NM_000137.4:c.96dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000128.1" sequenceAccession="NP_000128" sequenceVersion="1" change="p.Gly33fs">
            <Expression>NP_000128.1:p.Gly33fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374377.1" sequenceAccession="NM_001374377" sequenceVersion="1" change="c.96dup">
            <Expression>NM_001374377.1:c.96dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361306.1" sequenceAccession="NP_001361306" sequenceVersion="1" change="p.Gly33fs">
            <Expression>NP_001361306.1:p.Gly33fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001374380.1" sequenceAccession="NM_001374380" sequenceVersion="1" change="c.96dup">
            <Expression>NM_001374380.1:c.96dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001361309.1" sequenceAccession="NP_001361309" sequenceVersion="1" change="p.Gly33fs">
            <Expression>NP_001361309.1:p.Gly33fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2142090708" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000137.4(FAH):c.96dup (p.Gly33fs) AND Tyrosinemia type I" Accession="RCV001386192" Version="6">
        <ClassifiedConditionList TraitSetID="6267">
          <ClassifiedCondition DB="MedGen" ID="C0268490">Tyrosinemia type I</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2020-09-04" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-09-04" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-05-10" MostRecentSubmission="2024-04-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9101289</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9633815</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6267" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15974" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tyrosinemia type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Tyrosinemia type I</ElementValue>
                <XRef ID="Tyrosinemia+type+1/7281" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010161" DB="MONDO" />
                <XRef ID="410056006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hepatorenal tyrosinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fumarylacetoacetase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">FAH deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of fumarylacetoacetase</ElementValue>
                <XRef ID="124536006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TYRSN1</ElementValue>
                <XRef Type="MIM" ID="276700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Untreated tyrosinemia type I usually presents either in young infants with severe liver involvement or later in the first year with liver dysfunction and renal tubular dysfunction associated with growth failure and rickets. Untreated children may have repeated, often unrecognized, neurologic crises lasting one to seven days that can include change in mental status, abdominal pain, peripheral neuropathy, and/or respiratory failure requiring mechanical ventilation. Death in the untreated child usually occurs before age ten years, typically from liver failure, neurologic crisis, or hepatocellular carcinoma. Combined treatment with nitisinone and a low-tyrosine diet has resulted in a greater than 90% survival rate, normal growth, improved liver function, prevention of cirrhosis, correction of renal tubular acidosis, and improvement in secondary rickets.</Attribute>
                <XRef ID="NBK1515" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000264964" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568295" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2658" />
                <XRef ID="2658" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301688</ID>
                <ID Source="BookShelf">NBK1515</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Tyrosine, Tyrosinemia, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tryosine-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Elevated, Succinylacetone Normal, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Tyrosine-Normal-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Tyrosine Normal/Elevated, Succinylacetone Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="882" DB="Orphanet" />
              <XRef ID="C0268490" DB="MedGen" />
              <XRef ID="MONDO:0010161" DB="MONDO" />
              <XRef Type="MIM" ID="276700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3111978" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="9327061|MedGen:C0268490" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001586330" DateUpdated="2024-02-20" DateCreated="2021-05-10" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9101289</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9633815</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in FAH are known to be pathogenic (PMID: 9101289, 9633815). This variant has not been reported in the literature in individuals with FAH-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gly33Argfs*67) in the FAH gene. It is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FAH" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.80450415_80450416insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268490" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9000445" SubmissionDate="2024-04-12" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey=":Chr.15_80450415_T_TA|OMIM:276700" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004814152" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Illumina Laboratory Services, Illumina" OrgID="504895" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The FAH c.96dupA p.(Gly33ArgfsTer67) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. To our knowledge, this variant has not been reported in the peer-reviewed literature. This variant is not observed in version 2.1.1 of the Genome Aggregation Database. Based on the available evidence, the c.96dupA p.(Gly33ArgfsTer67) variant is classified as pathogenic for tyrosinemia, type I.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ICSLVariantClassificationCriteria RUGD 01 April 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/dy7elfgy/icslvariantclassificationcriteria_rugd_01_april_2020.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="15" alternateAllele="TA" referenceAllele="T" start="80450415" stop="80450415" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="276700" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14375523</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3111978" TraitType="Disease" MappingType="XRef" MappingValue="C0268490" MappingRef="MedGen">
        <MedGen CUI="C0268490" Name="Tyrosinemia type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9000445" TraitType="Disease" MappingType="XRef" MappingValue="276700" MappingRef="OMIM">
        <MedGen CUI="C0268490" Name="Tyrosinemia type I" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

